Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs LVNG RX
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict62/ 100
Grade C · #296LVNG RX
LVNG RX is a Delaware-registered telehealth platform (LVNG RX LLC) offering compounded semaglutide from $149/mo and tirzepatide from $249/mo, plus a lower-dose GLP-1 microdose program.
Visit LVNG RXThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 62/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. LVNG RX still earns its place — shoppers who want cash-pay shoppers drawn to a low semaglutide from-price who will confirm the real plan cost before paying.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results75
92
Real-world results75
97Price honesty28
97
Price honesty28
96Prescriber access46
96
Prescriber access46
88Formulary choice82
88
Formulary choice82
95Cancellation fairness88
95
Cancellation fairness88
93Member support65
93
Member support65
Price, coverage & features
| Metric | CoreAge Rx | LVNG RX |
|---|---|---|
| Verdict Score | 94/100 | 62/100 |
| Grade | A | C |
| Semaglutide | $149/mo | From $149/mo (starting dose, compounded) |
| Tirzepatide | $349/mo | From $249/mo (starting dose, compounded) |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
LVNG RX
What we like
- One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
- States you are charged nothing if a provider does not approve you for treatment
- Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
- Semaglutide from $149/mo is competitive against the wider compounded market
- Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide
The caveats
- Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
- Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
- Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
- The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
- No compounding pharmacy, medical group or individual clinician is named anywhere on the site
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want cash-pay shoppers drawn to a low semaglutide from-price who will confirm the real plan cost before paying.
Visit LVNG RX Read the full LVNG RX review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programmes closest to it, and the same shortlist for LVNG RX does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.